Federated Hermes Inc. Has $202.42 Million Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Federated Hermes Inc. decreased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 4.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,272,761 shares of the company’s stock after selling 169,473 shares during the quarter. Federated Hermes Inc. owned approximately 6.83% of Amphastar Pharmaceuticals worth $202,420,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. McGlone Suttner Wealth Management Inc. bought a new position in shares of Amphastar Pharmaceuticals in the fourth quarter valued at about $28,000. Point72 Middle East FZE acquired a new position in shares of Amphastar Pharmaceuticals in the fourth quarter valued at about $50,000. Ronald Blue Trust Inc. grew its stake in shares of Amphastar Pharmaceuticals by 821.5% in the third quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company’s stock valued at $55,000 after acquiring an additional 1,068 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Amphastar Pharmaceuticals by 99.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company’s stock valued at $58,000 after acquiring an additional 628 shares in the last quarter. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Amphastar Pharmaceuticals in the first quarter valued at about $74,000. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Down 1.5 %

Amphastar Pharmaceuticals stock traded down $0.59 during mid-day trading on Thursday, hitting $39.46. 71,963 shares of the stock were exchanged, compared to its average volume of 460,936. The firm’s fifty day simple moving average is $46.59 and its two-hundred day simple moving average is $51.23. The stock has a market capitalization of $1.93 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 0.98 and a beta of 0.84. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. Amphastar Pharmaceuticals, Inc. has a 12 month low of $35.62 and a 12 month high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The business had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. Analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.42 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMPH. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They set an “overweight” rating and a $60.00 price objective on the stock. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Amphastar Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $66.00.

Insider Activity

In other news, Director Floyd F. Petersen sold 500 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total value of $26,550.00. Following the transaction, the director now owns 80,333 shares in the company, valued at $4,265,682.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Michael A. Zasloff sold 12,500 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the sale, the director now owns 21,326 shares of the company’s stock, valued at $1,006,160.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Floyd F. Petersen sold 500 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total value of $26,550.00. Following the transaction, the director now directly owns 80,333 shares of the company’s stock, valued at approximately $4,265,682.30. The disclosure for this sale can be found here. Insiders have sold a total of 14,000 shares of company stock worth $660,860 over the last ninety days. Company insiders own 28.40% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.